Sanofi is developing strategies to control beta cell destruction in type 1 diabetes (T1D) through immunotherapy. Strategies could include targeting specific molecules on cells that may be of importance in disease pathogenesis.
Such approaches are in progress and candidate molecular targets of potential interest have been identified. As part of the next steps, our goal is to obtain a better understanding of the relevance of candidate molecules in T1D development. For this reason, in this project we aim to study whether molecules of interest are expressed in the pancreas; the location and identity of positive cells; and the relationship to disease. This will assist in the next key stages of drug development for T1D